Importantly, these clinical data directly correlate with our ex vivo findings clearly revealing a protective role for HMGA2 against TOP2A targeting drugs and, taken together, illustrates their importance for clinical strategies in particular for HMGA2‐positive AML patients. The gene discussed is TOP2A; the disease is acute myeloid leukemia.